Please assess the completion status of the following clinical trial:

Trial Title: Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Age \> 18 years~* Hemoglobin levels between \[ \> 9g/dl - \< 11 g/dl \] .~* Patient requiring erythropoietine beta treatment for a foreseeable duration of at least 8 weeks under the same chemotherapy protocol.~* Patient with cancer undergoing chemotherapy~* Patient without EPO within 6 months prior to current chemotherapy.~* WHO 2 performance status (Appendix 1).~* Patient information and signature of informed consent or legal representative~Exclusion criteria :~* Hemoglobin \< 9 g/dl or \> 11 g/dl~* Patient with cancer not treated with chemotherapy (targeted therapy, hormone therapy, etc...)~* Patient with cancer treated with concomitant radiation chemotherapy.~* Co-treated with Epo beta and scheduled transfusion prior to inclusion.~* Hypersensitivity to the active substance or one of the NeoRecormon excipients®~* Poorly controlled high blood pressure~* Pregnant woman, likely to be pregnant or breastfeeding,~* Persons deprived of liberty or under guardianship,~* Unable to undergo medical follow-up for geographic, social or psychological reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Erythropoietin beta (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).